Roche Holding AG (ROG.SW)
| Previous close | 340.75 |
| Open | 341.10 |
| Bid | 342.00 x 0 |
| Ask | 342.05 x 0 |
| Day's range | 339.75 - 343.35 |
| 52-week range | 290.55 - 345.55 |
| Volume | 1,573,263 |
| Avg. volume | 1,387,611 |
| Market cap | 295.481B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 20.70 |
| EPS (TTM) | 16.52 |
| Earnings date | 22 Jul 2021 |
| Forward dividend & yield | 9.10 (2.66%) |
| Ex-dividend date | 18 Mar 2021 |
| 1y target est | 259.86 |
- Globe Newswire
Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia
Four-year follow-up analysis from the phase III CLL14 study showed progression-free survival rate of 74.0% in previously untreated patients with chronic lymphocytic leukaemia (CLL) three years after completion of a one-year fixed-duration treatment with Venclexta/Venclyxto plus Gazyva/Gazyvaro1New phase III MURANO study data suggested certain genetic risk factors may help tailor treatments for patients with previously treated CLL2A post-hoc analysis from the phase III VIALE-A study in newly diag
- Business Wire
Genentech Announces Data at EHA2021 Reinforcing Efficacy of Venclexta Combinations in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
SOUTH SAN FRANCISCO, Calif., Jun 11, 2021--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the latest data from three pivotal Phase III studies of Venclexta® (venetoclax) – CLL14, MURANO and VIALE-A – to be presented at the European Hematology Association Virtual Congress, June 9-17 (EHA2021). Long-term follow-up data from the CLL14 and MURANO studies support the primary analysis of Venclexta in chronic lymphocytic leukemia (CLL) and the possibility of tailor
- Globe Newswire
New Roche data for Evrysdi show improved motor function in pre-symptomatic babies after one year and confirm safety profile in previously treated people with spinal muscular atrophy (SMA)
Data from JEWELFISH, the first trial in a diverse population aged 1 to 60 years with SMA who received prior treatment, showed a consistent safety profile and >2-fold increase in SMN protein levelsPre-symptomatic babies with SMA treated with Evrysdi for at least one year were able to sit, stand and walk in preliminary data from RAINBOWFISH studyEvrysdi has proven efficacy in adults, children and babies two months and older and is now approved in 44 countries worldwide Basel, 11 June 2021 - Roche
